Regulators adopt more orphan drugs

Adopt IP Protections to ensure Regulatory exclusivity for Orphan Drugs

orphan drugs present unique risks — the potential return on investment is inherently constrained by small patient populations and attendant reimbursement challenges. recognizing these challenges, some countries have passed laws designed to make the economic model associated with developing treatments for orphan diseases more attractive. the most meaningful incentive provided by the various orph...

Clozapine: is now the time for more clinicians to adopt this orphan?

Although many patients with schizophrenia fail to respond adequately to trials of 2 or more antipsychotics, utilization of clozapine for these patients remains low, despite recommendations for its use by accepted treatment guidelines. Some experts estimate that 5-10 times more patients could benefit from clozapine than who are now receiving it. Learning how to manage the unique side effect prof...

Orphan drugs revisited.

Commentary Orphan drugs revisited

C. MCCABE, A. TSUCHIYA, K. CLAXTON and J. RAFTERY From the Section of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Department of Economics, University of Sheffield, Sheffield, Department of Economics and Related Studies, University of York, York, and Wessex Institute for Health Research and Development, University of Southampton, Southam...

Orphan LuxR regulators of quorum sensing.

Bacteria can modulate their behavior by releasing and responding to the accumulation of signal molecules. This population co-ordination, referred to as quorum sensing, is prevalent in Gram-negative and Gram-positive bacteria. The essential constituents of quorum-sensing systems include a signal producer, or synthase, and a cognate transcriptional regulator that responds to the accumulated signa...